Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 165

1.

Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges.

De Caterina R, Goto S.

Vascul Pharmacol. 2016 Jun;81:1-14. doi: 10.1016/j.vph.2016.03.003. Epub 2016 Mar 16. Review.

PMID:
26994821
2.

Antithrombotic Therapy for Secondary Prevention in Patients With Diabetes Mellitus and Coronary Artery Disease.

Park Y, Franchi F, Rollini F, Angiolillo DJ.

Circ J. 2016 Mar 25;80(4):791-801. doi: 10.1253/circj.CJ-16-0208. Epub 2016 Mar 16.

3.

Oral anticoagulants in coronary heart disease (Section IV). Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease.

De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Collet JP, Halvorsen S, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Ricci F, Sibbing D, Siegbahn A, Storey RF, Ten Berg J, Verheugt FW, Weitz JI.

Thromb Haemost. 2016 Apr 1;115(4):685-711. doi: 10.1160/TH15-09-0703. Epub 2016 Mar 8.

PMID:
26952877
4.

Developing drugs for use before, during and soon after percutaneous coronary intervention.

Gargiulo G, Moschovitis A, Windecker S, Valgimigli M.

Expert Opin Pharmacother. 2016 Apr;17(6):803-18. doi: 10.1517/14656566.2016.1145666. Epub 2016 Mar 3.

PMID:
26800365
5.

Antithrombotic therapy in patients with combined coronary heart disease and atrial fibrillation.

Thompson PL, Morton AC.

Panminerva Med. 2016 Mar;58(1):23-33. Epub 2015 Dec 11.

PMID:
26658287
6.

Practical experience with ticagrelor: an Australian and New Zealand perspective.

Harding SA, Van Gaal WJ, Schrale R, Gunasekara A, Amerena J, Mussap CJ, Aylward PE.

Curr Med Res Opin. 2015 Aug;31(8):1469-77. doi: 10.1185/03007995.2015.1058247. Epub 2015 Jun 30. Review.

PMID:
26086451
7.

Risk and benefit of direct oral anticoagulants or PAR-1 antagonists in addition to antiplatelet therapy in patients with acute coronary syndrome.

Gao F, Shen H, Wang ZJ, Yang SW, Liu XL, Zhou YJ.

Thromb Res. 2015 Aug;136(2):243-9. doi: 10.1016/j.thromres.2015.05.025. Epub 2015 May 27.

PMID:
26037286
8.
9.

Why we should not skip aspirin in cardiovascular prevention.

Schrör K.

Hamostaseologie. 2016 Feb 10;36(1):33-43. doi: 10.5482/hamo-14-10-0048. Epub 2015 Apr 20.

PMID:
25891122
10.

Direct oral anticoagulants in the secondary prevention of stroke and transient ischemic attack in patients with atrial fibrillation.

Arnao V, Agnelli G, Paciaroni M.

Intern Emerg Med. 2015 Aug;10(5):555-60. doi: 10.1007/s11739-015-1226-4. Epub 2015 Apr 11.

PMID:
25862436
11.

Risks and benefits of triple oral anti-thrombotic therapies after acute coronary syndromes and percutaneous coronary intervention.

Alfredsson J, Roe MT.

Drug Saf. 2015 May;38(5):481-91. doi: 10.1007/s40264-015-0286-8. Review.

PMID:
25829216
12.

The spectrum of thrombin in acute coronary syndromes.

Giri S, Jennings LK.

Thromb Res. 2015 May;135(5):782-7. doi: 10.1016/j.thromres.2015.02.013. Epub 2015 Feb 21. Review.

PMID:
25764910
13.

New oral anticoagulants and perioperative management of anticoagulant/antiplatelet agents.

Rahman A, Latona J.

Aust Fam Physician. 2014 Dec;43(12):861-6. Review.

PMID:
25705736
14.

[Anticoagulant therapy in secondary prevention of coronary events].

Bultas J.

Vnitr Lek. 2014 Dec;60(12):1023-32. Review. Czech.

PMID:
25692828
15.

Role of oral anticoagulants in patients after an acute coronary syndrome.

Carreras ET, Mega JL.

Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):520-4. doi: 10.1161/ATVBAHA.114.303401. Epub 2015 Jan 22. Review.

16.

New approaches to inhibiting platelets and coagulation.

Depta JP, Bhatt DL.

Annu Rev Pharmacol Toxicol. 2015;55:373-97. doi: 10.1146/annurev-pharmtox-010814-124438. Review.

PMID:
25562644
17.

The use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disorders.

Cohen AT, Imfeld S, Markham J, Granziera S.

Thromb Res. 2015 Feb;135(2):217-25. doi: 10.1016/j.thromres.2014.11.036. Epub 2014 Dec 13. Review.

PMID:
25541030
18.

Bivalirudin for acute coronary syndromes: premises, promises and doubts.

Capodanno D, De Caterina R.

Thromb Haemost. 2015 Apr;113(4):698-707. doi: 10.1160/TH14-09-0765. Epub 2014 Dec 18. Review.

PMID:
25519159
19.

Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?

Huber K, Bates ER, Valgimigli M, Wallentin L, Kristensen SD, Anderson JL, Lopez Sendon JL, Tubaro M, Granger CB, Bode C, Ohman EM, Steg PG.

Am Heart J. 2014 Nov;168(5):611-21. doi: 10.1016/j.ahj.2014.06.014. Epub 2014 Jun 26. Review.

PMID:
25440788
20.

[Antithrombotic therapy and atrial fibrillation. Dual or triple therapy after acute coronary syndrome and stent?].

Zeymer U, Zahn R.

Herz. 2014 Nov;39(7):814-8. doi: 10.1007/s00059-014-4164-4. German.

PMID:
25336242
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk